We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > protalix

News List

Protalix BioTherapeutics, Chiesi Complete Enrollment for Trial of Pegunigalsidase Alfa americanpharmaceuticalreview
September 25, 2019
Protalix BioTherapeutics and its development and commercialization partner, Chiesi Farmaceutici announced the completion of enrollment in their Phase III BALANCE clinical study of pegunigalsidase alfa ...
Protalix BioTherapeutics Appoints President, CEO contractpharma
May 29, 2019
Bashan brings more than 20 years of experience in the pharmaceutical industry.
Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data biospace
March 14, 2018
Protalix Biotherapeutics, Inc. believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered via injection or infusion.
Protalix Wins FDA Approval as Multi-Product Facility contractpharma
June 05, 2017
Protalix BioTherapeutics received approval from the FDA for a Supplemental New Drug Application (sNDA) allowing the company to convert its manufacturing facility in Carmiel, Israel, from a single dedicated product facility to a multi-product facility.